2 Efficacy and safety of lenvatinib plus pembrolizumab in patients with previously treated ovarian cancer in the multicohort phase 2 LEAP-005 study. (13th November 2020)

• Record Type: Journal Article
• Authors: González-Martín, A; Chung, H; Saada-Bouzid, E; Yanez, E; Senellart, H; Cassier, PA; Basu, B; Ghori, R; Kubiak, P; Smith, A; Norwood, K; Lwin, Z
• Is Part Of: International journal of gynecological cancer. Volume 30(2020)Supplement 3
• Page Start: A1
• Page End: A2
• Publication Date: 2020-11-13
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2020-IGCS.2
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction: Lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, plus pembrolizumab, a programmed death-1 immune checkpoint inhibitor, demonstrated promising clinical benefit in a previous phase Ib/II trial across several cancer types (ClinicalTrials.gov, NCT02501096 ). We assessed clinical outcomes with lenvatinib plus pembrolizumab in patients with ovarian cancer in the ongoing, open-label, multicohort, phase 2 LEAP-005 study (ClinicalTrials.gov, NCT03797326 ). Methods: Female patients aged ≥18 years with histologically/cytologically confirmed, metastatic/unresectable ovarian cancer, measurable disease per RECIST v1.1, ECOG performance status 0/1, and 3 prior lines of therapy were enrolled. Patients received lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles, or until confirmed disease progression or unacceptable toxicity. Primary endpoints were objective response rate (ORR; response assessed every 9 weeks for 54 weeks, then every 12 weeks, by blinded independent central review per RECIST v1.1) and safety. Secondary endpoints included disease control rate, duration of response, and progression-free survival. Results: 31 patients with ovarian cancer received ≥1 dose of lenvatinib plus pembrolizumab in LEAP-005 (median age 62 years [range 40–76]); median study follow-up was 7.8 months (range, 4.6–12.4) as of April 10, 2020. ORR was 32% (95% CI, 17–51); other efficacy endpoints were also favorable (table 1 ). Treatment-related adverse events occurred in 29 (94%) patients (table 1 ). Conclusion: Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure.